U.S. Markets closed

Lipocine Inc. (LPCN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.4600+0.0400 (+2.82%)
At close: 4:00PM EDT

1.4100 -0.05 (-3.42%)
After hours: 7:28PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4700
Open1.4700
Bid1.4300 x 1000
Ask1.4500 x 3200
Day's Range1.4150 - 1.5099
52 Week Range0.4300 - 2.4200
Volume1,333,161
Avg. Volume5,196,026
Market Cap128.904M
Beta (5Y Monthly)0.53
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • LPCN: Lipocine’s LiFT Results: A Comparison with Peers
    Zacks Small Cap Research

    LPCN: Lipocine’s LiFT Results: A Comparison with Peers

    By John Vandermosten, CFA NASDAQ:LPCN Positive Topline Phase II Results from Ongoing LiFT Study, Update Includes Comparison Lipocine Inc. (NASDAQ:LPCN) announced positive topline data from LiFT (1), a Phase II study of its candidate LPCN 1144 in biopsy-confirmed, non-cirrhotic male NASH patients with F1-F3 fibrosis. LiFT reported that both treatment arms met the primary endpoint with a high

  • LPCN: LiFT: Twelve-week Topline Touts Statistical Significance
    Zacks Small Cap Research

    LPCN: LiFT: Twelve-week Topline Touts Statistical Significance

    By John Vandermosten NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Positive Topline Phase II Results from Ongoing LiFT Study Lipocine Inc. (NASDAQ:LPCN) announced positive topline data from LiFT (1), a Phase II study of its candidate LPCN 1144 in biopsy-confirmed, non-cirrhotic male Non-alcoholic Steatohepatitis (NASH) patients with F1-F3 fibrosis. LiFT reported that both treatment arms met the

  • Zacks Small Cap Research

    LPCN: Tentative Approval Granted, Target Up

    By John Vandermosten NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT FDA Grants Tentative Approval to Tlando After multiple extensions from the August 2020 target action date, the FDA granted tentative approval of Lipocine’s (NASDAQ: LPCN) Tlando on December 8th. Tlando met all required quality, safety and efficacy standards necessary for approval; however, marketing of Tlando will not be allowed